Reconstructed tissues, patient-derived organoids, primary cells, and the testing services that turn them into decisions - all under one ISO 9001:2015 roof.
Each pillar is a full sub-platform with its own catalogue, methods and validation. Pick one to dive in.
Beyond the BioDEpi flagship, ten further BioD models span skin, mucosal and epithelial tissue — from in-market staples to the R&D pipeline.
NAMs are human-relevant test systems — reconstructed human tissues, patient-derived organoids and primary cells — that replace or reduce animal testing while predicting human responses more accurately, because a model built from human cells answers a human question.
Yes. Models are built to standardised, recognised endpoints with histology and barrier-integrity (TEER) confirmation, and our testing services include OECD-aligned regulatory submission support across personal care, pharma and chemicals.
BioDEpi is reconstructed human epidermis — a multilayered, differentiated keratinocyte model. BioDFT is a full-thickness skin model that adds a fibroblast-populated dermal compartment beneath the epidermis, for assays that need dermal–epidermal interaction.
Both. You can source in-market tissue models, organoids and primary human cells, or commission our scientists to design, run and report studies end-to-end — from claim substantiation to regulatory submission.
BioDimension operates an ISO 9001:2015 certified facility in Bommasandra Industrial Area, Bengaluru, Karnataka, India, with capacity for 200 units per production cycle.
ResearchReconstructed human tissues reproduce the architecture, barrier function and molecular responses of real human tissue — so results translate to people, not a different species.
PlatformHow the OrgCan™ platform grows 3D organoids directly from patient biopsies to preserve tumour architecture, microenvironment and genetics for precision oncology.
CompanyA look at the 6,000 sq ft Bengaluru facility — three cell-culture labs, a microbial lab, and an analytical suite — built to run complex biofabrication at scale.
Our scientists build bespoke tissue and organoid platforms around your research question and regulatory pathway.
